We tested 42 tetrapeptides for their ability to bind to the rat brain p2l' protein farnesyltransferase as estimated by their ability to compete with p2lH"-in a farnesyltransfer assay. Peptides with the highest affinity had the structure Cys-Al-A2-X, where positions Al and A2 are occupied by aliphatic amino acids and position X is-occupied by a COOHterminal methionine, serine, or phenylalanine. Charged residues reduced affinity slightly at the Al position and much more drastically at the A2 and X positions. Effective inhibitors included tetrapeptides corresponding to the COOH termini of all animal cell proteins known to be farnesylated. In contrast, the tetrapeptide Cys-Ala-Ile-Leu (CARL), which corresponds to the COOH termini of several neural guanine nucleotide binding (G) protein y subunits, did not compete in the farnesyl-transfer assay. Inasmuch as several of these proteins are geranylgeranylated, the data suggest that the two isoprenes (farnesyl and geranylgeranyl) are transferred by different enzymes. A biotinylated heptapeptide corresponding to the COOH terminus of p21K'-1B was farnesylated, suggesting that at least some of the peptides serve as substrates for the transferase. The data are consistent with a model in which a hydrophobic pocket in the protein farnesyltranferase recognizes tetrapeptides through interactions with the cysteine and the last two amino acids.
A farnesyl residue is attached in thioether linkage to the COOH-terminal cysteine of a variety of intracellular membrane-associated proteins. The list includes cellular p21lS proteins (1), nuclear lamin B (2) , and the 'y subunit of bovine transducin (3) . This modification is also found on mating factors secreted by fungi (4, 5) .
In each case the farnesylated cysteine is initially the fourth residue from the COOH terminus (for review, see ref. 6 ). Farnesylation is followed by proteolytic removal of the three terminal residues and carboxylmethylation of the cysteine. These reactions render the COOH termini hydrophobic, presumably facilitating the initial attachment of the proteins to cell membranes. In some instances the hydrophobicity is increased by palmitoylation of nearby cysteines. Inspection of the sequences of the known farnesylated proteins has defined a weak consensus sequence for farnesylation that consists of Cys-A1-A2-X, where positions Al and A2 are occupied by aliphatic amino acids and position X is occupied by an undefined amino acid (7, 8) .
The likely donor of farnesyl residues is farnesyl pyrophosphate (FPP), an intermediate in the synthesis of sterols and polyisoprenes in eukaryotic cells (9) . Recently, we have isolated from rat brain an enzyme that transfers a farnesyl group from [3H]FPP to p2lHa-as protein (10, 11) . The purified enzyme preparation contains two proteins, each with an apparent molecular mass ofabout 50 kDa, that appear to form a heterodimer (10, 11) . The enzyme recognizes sequences as short as four amino acids provided that cysteine is at the fourth position from the COOH terminus. Recognition was demonstrated by the ability ofthese peptides to compete with p21Ha-ras in the protein farnesyltransferase assay. In addition, the enzyme adhered to an affinity column containing a hexapeptide corresponding to the COOH-terminal sequence of p2lKi-msB. A similar enzymatic activity was identified by Schaber et al. (12) in crude extracts of bovine brain.
The above findings suggest that the recognition site for the protein farnesyltransferase consists only of cysteine and the three COOH-terminal residues. This conclusion is consistent with the observation that the various classes of farnesylated proteins do not share any sequences except the Cys-A1-A2-X motif. It is also in line with the experiment of Hancock et al. (8) , who attached a DNA sequence encoding the COOHterminal four amino acids of p21Haras to the 3' end of a cDNA encoding bacterial protein A. The chimeric protein was prenylated when it was expressed in COS cells, as judged by studies of [3H]mevalonate labeling. Subsequent enzymes in the protein farnesylation pathway may also recognize limited COOH-terminal sequences. Thus, Stephenson and Clarke (13) recently showed that the last enzyme in the pathway, the carboxylmethyltransferase, recognizes short peptides that contain a COOH-terminal farnesylcysteine.
In addition to the farnesyl group, which contains 15 carbon atoms, a 20-carbon polyisoprenoid, geranylgeranyl, can also be attached covalently to proteins (14, 15) . This modification appears to be more common than farnesylation in animal cells, but the nature of the recognition sequence is not yet understood. The only known examples ofgeranylgeranylated proteins are the y subunits of guanine nucleotide binding proteins (G proteins) from bovine brain (16) and rat PC12 cells (17) , some of which have the COOH-terminal sequence Cys-Ala-Ile-Leu (CAIL) (18, 19) . Whether these proteins are modified by the same enzyme that transfers farnesyl groups to other proteins is unknown.
To learn more about the peptide recognition site on the protein farnesyltransferase, we have carried out a study of the ability of various tetrapeptides to compete with p21Ha-,s for acceptance of a farnesyl residue. As a framework for these peptides, we have used the COOH terminus of p2lKi-sB, Cys-Val-Ile-Met (CVIM), which was the highest affinity peptide among those studied (10) . The results indicate that the Al position of the Cys-Al-A2-X motif will accept a variety of amino acids, but the A2 position is much more strict in its requirement for an uncharged residue. At the X position, methionine, phenylalanine, and serine are strongly preferred. 
MATERIALS AND METHODS
Peptides. Peptides were prepared by established procedures of solid-phase synthesis (20) . Tetrapeptides were synthesized on the Milligen 9050 synthesizer using Fmoc (9-fluorenylmethyloxycarbonyl) chemistry. After deprotection of the last residue, a portion of the resin was used to make the N-acetylmodified version of CVIM. This was done off-line in a solution of acetic anhydride and dimethylformamide at pH 8 (adjusted with diisopropylethylamine). The acetylated and unacetylated peptides were cleaved with 50 ml of trifluoroacetic acid/ phenol, 95:5 (vol/vol), plus approximately 1 ml of ethanedithiol added as a scavenger. The N-octyl-modified version of CVIM was synthesized on an Applied Biosystems model 430A synthesizer using tBoc (t-butoxycarbonyl) chemistry. The octyl group was added in an amino acid cycle using octanoic acid. The peptide was cleaved from the resin at 0C with a 10:1:1 ratio of HF (ml)/resin (g)/anisole (ml). The peptides were purified by high pressure liquid chromatography (HPLC) on a Beckman C18 reverse-phase column (21.1 cm x 15 cm), eluted with a water/acetonitrile gradient containing 0.1% trifluoroacetic acid. Identity was confirmed for all peptides by quantitative amino acid analysis and for the NH2-terminally modified peptides by fast atom bombardment mass spectrometry. Just prior to use, each peptide was dissolved at a concentration of 0.8 mM in 10 mM dithiothreitol (DTT) except for several of the most hydrophobic peptides, which were dissolved at a concentration of 1 mM in dimethyl sulfoxide/10 mM DTT. All dilutions were made in 10 mM DTT in the absence of dimethyl sulfoxide.
Biotinylated Lys-Thr-Ser-Cys-Val-Ile-Met (KTSCVIM) was synthesized on an Applied Biosystems model 430A synthesizer. The biotin group was added after removal of the NH2-terminal protecting group before cleavage of the peptide from the resin. Specifically, a 4-fold molar excess of biotin 4-nitrophenyl ester was added to 0.5 g of resin in 75 ml of dimethylformamide at pH 8 and incubated for 5 hr at room temperature. Cleavage, identification, and purification were carried out as described above.
To synthesize S-acetoamido-CVIM, purified CVIM was dissolved at a final concentration of 1 mM in 0.1 ml of 0.5 M Tris-Cl, pH 8.0/15 mM DTT. The tube was flushed with nitrogen for 2 min, sealed, and incubated for 2.5 hr at 37°C to reduce the cysteine residue, after which iodoacetamide was added to achieve a final concentration of 35 mM. After incubation for 15 min at 37°C, the reaction was stopped by addition of 10 mM DTT. Complete alkylation of CVIM was confirmed by fast atom bombardment mass spectrometry and HPLC. The molecular mass of the product corresponded to the expected molecular mass of S-acetoamido-CVIM.
Assay 
RESULTS
To screen peptides for their affinity for protein farnesyltransferase, we measured the ability of the peptides to compete with p21Ha-ras for acceptance of [3H]farnesyl from [3H]FPP as catalyzed by a partially purified rat brain protein farnesyltransferase. As a reference point for the peptides, we used CVIM, which corresponds to the COOH-terminal sequence of p21Ki-rasB. Fig. 1 A-C shows a series of typical experiments in which we systematically substituted alanine, lysine, or leucine, respectively, at each of the three positions after cysteine in CVIM. In each experiment the results were compared with those obtained with CVIM. Alanine and lysine were tolerated only at the Al position. Insertion of these amino acids at the A2 or X positions decreased the affinity for the enzyme by more than 30 times, as estimated by the concentration required for 50% inhibition. Leucine for the partially purified enzyme by 6-to 20-fold, with half-maximal inhibition occurring at 10-25 nM ( Fig. 2A ; also see Fig. 4 ). No such effect was observed when phenylalanine was inserted at either of the other two positions.
In addition to performing assays with p21Ha-s as a substrate, we also performed assays in which the substrate was the biotinylated heptapeptide KTSCVIM, which contains the 4 COOH-terminal amino acids of p21Ki-(IB (21) . The biotin was attached to the NH2 terminus by coupling to the resinattached peptide. The [3H]farnesyl-labeled product was isolated by allowing it to bind to beads coated with streptavidin (11). Fig. 2 A and B shows that the peptide CVFM was 10-to 20-fold more potent than CVIM when either p2lHaas or the biotinylated heptapeptide was used as acceptor, respectively. In contrast to the experiments in Fig. 1 , which were conducted with a partially purified enzyme, experiments shown in Fig. 2 were carried out with a homogeneous preparation of affinitypurified protein farnesyltransferase.
The free sulfhydryl group of the cysteine is likely required for tetrapeptide inhibition, as indicated by the finding that derivitization with iodoacetamide abolished inhibitory activity (Fig. 3A) . A blocked NH2 terminus is not required, as indicated by similar inhibitory activity ofN-acetyl-CVIM and N-octyl-CVIM (Fig. 3B ) compared to that of CVIM (Fig. 3A) . Fig. 4 summarizes the results of all competition assays in which we made substitutions in the CVIM sequence. The results are presented in terms of the peptide concentration required for 50% inhibition. Table 1 summarizes the results of other experiments in which we studied tetrapeptides corresponding to the COOH termini of 19 proteins, many of which are known to be farnesylated. The implications of these studies are discussed below. DISCUSSION The current data extend previous observations on the p2lS protein farnesyltransferase (10, 11) acids of the Cys-A1-A2-X type. As a reference sequence for these studies, we used the peptide CVIM, which inhibited the protein farnesyltransferase by 50%o at a concentration of 0.15 ,M. Substitution of various amino acids into this framework yielded peptides that gave 50% inhibitions at a spectrum of concentrations ranging from 0.025 MM (CVFM) to greater than 50 MM (Fig. 4) .
In general, the highest inhibitory activities were achieved when the Al and A2 positions were occupied with nonpolar aliphatic or aromatic amino acids. This stringency was more severe at the A2 than at the Al position. Thus, peptides containing lysine or glutamic acid at the Al position gave 50% inhibition at 0.7 and 1.5 AM, respectively. When these two residues were inserted at the A2 position, the affinity for the enzyme declined by more than 50-fold. Glycine and proline lowered inhibitory activity moderately at the Al position (50% inhibition at 3 and 7 MM) and somewhat more severely at the A2 position (8 and 20 MM). The X position showed the highest stringency. When the first three amino acids were CVI, methionine was the preferred residue at the X position but phenylalanine and seine were tolerated with only modest losses in activity (0.5 and 1 MM, respectively). Aliphatic residues and proline were disruptive at position X, with 50%o inhibitions in the range of 5-11 MM. Glutamic Table 1 ). and glycine were not tolerated at all; 50% inhibition required concentrations above 40 AuM.
A study of tetrapeptides corresponding to the COOH termini of known proteins ( Table 1 ) gave results that were generally in keeping with those obtained with the substituted CVIM peptides. They provided the additional information that glutamine and cysteine are well tolerated at the X position [Cys-Cys-Val-Gln (CCVQ) and Cys-Ile-Ile-Cys (CIIC), respectively]. All of the proteins that are known to be farnesylated in intact cells (indicated by the asterisks in Table  1 ) followed the rules outlined above, and all inhibited farnesylation at relatively low concentrations (5 AM or below) with the exception of the Cys-Thr-Val-Ala (CTVA) sequence, which is found in the mating factor of R. toruloides (22) . This peptide inhibited the rat brain protein farnesyltransferase by 50% only at the high concentration of 30 ,M. It is likely that the protein farnesyltransferase in this fungal species has a different specificity than that of the rat brain.
The peptide CAIL, which corresponds to the COOH terminus of some of the y subunits of bovine brain G proteins (18, 19) , did not compete efficiently with p21Ha-,s for farnesylation (Table 1) . We observed 50%o inhibition only at the highest concentration tested (100 ,uM). The inhibitory activity was lower than that of Cys-Val-Ile-Leu (CVIL; 11 ,uM) or Cys-Ala-Ile-Met (CAIM; 0.15 ,uM). Thus, the combination of alanine at the Al position and leucine at the X position is more detrimental than either single substitution. This finding is particularly relevant since the y subunits ofG proteins from bovine brain (16) and rat PC12 cells (17) have been shown to contain a geranylgeranyl rather than a farnesyl. These findings suggest the existence of a separate geranylgeranyl transferase that favors CAIL and perhaps other related sequences.
The experiments with the biotinylated heptapeptide ( Fig.  2B and ref. 11 ) confirm that at least some ofthe short peptides act as substrates for the enzyme. The saturation curves relating reaction velocity to the concentration of either p21Ha-,s or the biotinylated heptapeptide are complex and sigmoidal. The inhibition curves with the various peptides differ from classic competitive inhibition curves (data not shown). Finally, as mentioned in an earlier paper (10), the maximal velocity of the purified enzyme is relatively low. These findings suggest that the binding of the peptides to the enzyme is not a simple equilibrium reaction. Rather, there may be slow binding that requires conformational change.
The observation that the Al position shows a relaxed amino acid specificity suggests that the residue at this position may not contact the famesyltransferase directly. Rather, the contacts may involve only the cysteine and the residues at the A2 and X positions. A working model for the active site ofthe protein farnesyltransferase places the peptide substrate in an extended conformation such that the side chains of the cysteine and the A2 residues face the enzyme and the side chain of the Al residue faces the solvent. A largely hydrophobic pocket of the enzyme apparently interacts with the X group of the Cys-Al-A2-X-containing substrate.
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